Insiders' Blog
Sponsored by: Subscribe to EasyStockAlerts.com Now & Get The News Before Everyone Else!
Following Today's Kosan (KOSN) Buyout, Investors Look for Next Biotech Deal
More News related to AFFY
- Affymax, Inc. (AFFY) Executive Officer to Ring the NASDAQ Stock Market Closing Bell
- Affymax Completes Enrollment in Phase 3 Program for Hematide in Chronic Renal Failure with Completion of Enrollment in EMERALD 2, the Final of Four Phase 3 Clinical Trials of Hematide(TM)
- Affymax to Present at Lazard Capital Markets Conference
- Affymax to Webcast Analyst and Investor Event on November 20, 2008
- Affymax Completes Enrollment in EMERALD 1, the Third of Four Phase 3 Clinical Trials of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients
More News related to ARQL
- ArQule, Inc. to Present at Lazard Capital Markets Healthcare Conference
- Beacon Equity Issues Technical Trade Alerts on Market Movers: OPTR, RNWK, ARQL, CROX, WRES, LWSN
- ArQule (ARQL) Tops Q3 Views; Boosts FY08 Outlook
- ArQule Announces Third Quarter Fiscal 2008 Results
- ArQule and Daiichi-Sankyo Enter Into Strategic R&D Partnership to Progress Novel Compounds to Target Cancer
More News related to BMRN
- Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics
- BioMarin to Present at the Credit Suisse Healthcare Conference
- BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
- BioMarin Announces Third Quarter 2008 Financial Results
- BioMarin Pharma (BMRN) Announces Results from Phase 2a Study of 6R-BH4
Following today's buyout of small biotech Kosan Biosciences, Inc. (NASDAQ: KOSN) by Bristol-Myers Squibb (NYSE: BMY) at a 200%+ premium, investors are on the lookout for the next biotech deal.
Today's deal follows other recent biotech takeovers including Millennium Pharmaceuticals (NASDAQ: MLNM), Sirtris Pharmaceuticals (Nasdaq: SIRT), Encysive Pharmaceuticals Inc. (Nasdaq: ENCY), and Restore Medical, Inc. (NASDAQ: REST).
Here are some biotech companies that could be next to be acquired: Onyx Pharmaceuticals (NASDAQ: ONXX), OSI Pharmaceuticals (NASDAQ: OSIP), ImClone (NASDAQ: IMCL), ISIS Pharmaceuticals (NASDAQ: ISIS), BioMarin Pharmaceutical (NASDAQ: BMRN), ArQule (NASDAQ: ARQL), Regeneron (NASDAQ: REGN), Affymax (NASDAQ: AFFY), Medivation (NASDAQ: MDVN).
Related Categories
Insiders' BlogRumors
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
